RxDoctor Payments Data

Neil Goldstein, MD

Vascular & Interventional Radiology · Irvine, CANPI 1235165226

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (35.5%), other and food and beverage — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Boston Scientific at 50.5% of the total. Reporting peaked in 2019 at $22,175 and has fallen 57.7% since, to $9,371 in 2025.

$56,286in general payments, 2019–2025

Across 487 payments — averaging $115.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$28K
  • Angiodynamics, Inc.$18K
  • Medtronic$2K
  • Mozarc Medical US LLC$1K
  • Tactile Systems Technology Inc$1K
  • Johnson & Johnson$716
  • plus $5K from 24 others

What the payments were for

  • Speaking & faculty fees$20,00036%
  • Travel & lodging$3,1276%
  • Food & beverage$16,38829%
  • Other$16,77130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,286 in reported general payments places this provider in the 85th percentile of 504 vascular & interventional radiology providers in California.

See all vascular & interventional radiology providers in California →

Medicare billing

Part B allowed, 2024
$443,569
Medicare patients
378
Services billed
2,064

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban47$51,457
Repatha SureclickEvolocumab40$27,529
EliquisApixaban27$16,268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$716$51,45747 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 504 vascular & interventional radiology providers in California.

Other vascular & interventional radiology in Irvine

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →